Current Market Access to Migraine Medications

The FDA in September approved two new migraine drugs: Eli Lilly and Co.'s Emgality and Teva Pharmaceuticals' Ajovy, which will compete with Aimovig from Amgen Inc. and Novartis AG. For most migraine medications on the market, more than half of covered lives are under the preferred tier/preferred with prior authorization or step therapy and covered tier/covered with PA/ST, as of November 2018. The chart below shows how migraine medications are covered among commercial health plans, health exchange plans and Medicare and Medicaid programs under the pharmacy benefit.

NOTE: The number of total covered lives is 302.1 million. For Migranal, about 0.1% of covered lives are under the generic (preferred) tier.

SOURCE: Managed Markets Insight & Technology, LLC database as of November 2018.